Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status

Abstract

Background Oncogenic K-Ras signaling highly relies on the canonical Ras/MEK/ERK pathway to contribute to pancreatic cancer progression. However, numerous efforts of MEK inhibitors have failed to provide an optimal antitumor effect for pancreatic cancer in practice. The aim of the present work was to develop a more efficacious therapeutic intervention for MEK inhibitors through combination with histone deacetylase (HDAC) inhibitor MPT0E028. Methods The effects of combined therapy on cell viability, apoptosis, protein, and RNA expressions were determined by MTT assay, flow cytometry, western blotting, and quantitative PCR analysis. The AsPC-1 xenograft was used to assess antitumor effects in vivo . Results The co-administration of MPT0E028 and MEK inhibitor yielded synergistic effects on cell viability suppression both in K-Ras mutated and wild-type pancreatic cancer cells and also markedly triggered cell apoptosis. Surprisingly, ERK and epidermal growth factor receptor (EGFR) were activated by the long-term and low-concentration treatment of MPT0E028 or another HDAC inhibitor alone. Whereas, the pharmacological attenuation of ERK signaling dramatically abolished the MPTE028-induced p-ERK and EGFR expression. Overexpression of HDAC4, HDAC6, and MEK, respectively, reversed the cell death induced by the combined treatment. Finally, the combined treatment decreased the tumor volume in an AsPC-1 xenograft model compared to each individual treatment alone. Conclusions The synergistic anti-survival effect of the combination was suggested to occur via compensation of the MEK inhibitor for activated ERK. Our results indicate that this combination strategy could benefit patients with pancreatic cancer beyond K-Ras status. Electronic supplementary material The online version of this article (10.1186/s13148-019-0681-6) contains supplementary material, which is available to authorized users.

Bioinformatics Data Mining Repurposes the JAK2 (Janus Kinase 2) Inhibitor Fedratinib for Treating Pancreatic Ductal Adenocarcinoma by Reversing the KRAS (Kirsten Rat Sarcoma 2 Viral Oncogene Homolog)-Driven Gene Signature

“…Our results suggest that the anticancer activity of HDAC inhibitors is unrelated to KRAS mutation status. Consistently, previous studies found that pan-HDAC inhibitors (vorinostat and AR-42) exhibit similar cytotoxicity in both KRAS WT and mutant PDAC cells [58,59]. However, it was also reported that a HDAC inhibitor, romidepsin, preferentially induces apoptosis in cancer cells harboring mutant KRAS [60].…”

Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity

“…HDAC inhibitors could efficiently suppress c-FLIPL expression augmenting MEK inhibitor-induced cell death. HDAC inhibition also proved successful in mutant KRAS pancreatic cancer [204]. Here, the treatment with the HDAC inhibitor MPT0E028 in combination with a MEK inhibitor yielded synergistic effects to defeat the intrinsic resistance to ERK pathway inhibitors.…”

Synergistic Lethal Mutagenesis of Hepatitis C Virus

“…Synergistic interactions among drugs are particularly important when the objective is suppression of pathogen replication to prevent the selection of treatmentresistant escape mutants. This is an objective for any pathogenic entity, be they genetically variable and heterogeneous DNA and RNA viruses, protozoa, or cancer cells (71,(81)(82)(83). A previous case of mutation type-driven antiviral reinforcement involved APOBEC3G (A3G; a human deaminase naturally expressed in cells) and 5-azacytidine (5-AZC).…”